Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hikma Adds Sesen’s Vicineum To MENA Brands

Deal Allows Branded Cancer Treatment To Be Sold In 19 Markets

Executive Summary

Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.

You may also be interested in...



Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos

Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.

Hikma Offers Update On Plans For Advair Rival

Hikma has provided a trading update that sheds fresh light on plans for its delayed Advair generic, as well as revealing some new launches.

Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel